CL2007002175A1 - Compuestos derivados de 2,5-difenil-1h-imidazol, moduladores de la actividad de la senda de hedgehog, util para el tratamiento de cancer de piel sin melanoma, mieloma, linfoma, soriasis, cancer pancreatico, cancer de prostata, meduloblastoma, carcino - Google Patents
Compuestos derivados de 2,5-difenil-1h-imidazol, moduladores de la actividad de la senda de hedgehog, util para el tratamiento de cancer de piel sin melanoma, mieloma, linfoma, soriasis, cancer pancreatico, cancer de prostata, meduloblastoma, carcinoInfo
- Publication number
- CL2007002175A1 CL2007002175A1 CL200702175A CL2007002175A CL2007002175A1 CL 2007002175 A1 CL2007002175 A1 CL 2007002175A1 CL 200702175 A CL200702175 A CL 200702175A CL 2007002175 A CL2007002175 A CL 2007002175A CL 2007002175 A1 CL2007002175 A1 CL 2007002175A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer
- prastoma
- carculobo
- soriasis
- difenil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83331806P | 2006-07-25 | 2006-07-25 | |
| US94265007P | 2007-06-07 | 2007-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007002175A1 true CL2007002175A1 (es) | 2008-06-13 |
Family
ID=38962752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200702175A CL2007002175A1 (es) | 2006-07-25 | 2007-07-25 | Compuestos derivados de 2,5-difenil-1h-imidazol, moduladores de la actividad de la senda de hedgehog, util para el tratamiento de cancer de piel sin melanoma, mieloma, linfoma, soriasis, cancer pancreatico, cancer de prostata, meduloblastoma, carcino |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7928133B2 (es) |
| EP (1) | EP2044065A2 (es) |
| JP (1) | JP2009544730A (es) |
| KR (1) | KR20090031789A (es) |
| AR (1) | AR062100A1 (es) |
| AU (1) | AU2007276788A1 (es) |
| BR (1) | BRPI0714663A2 (es) |
| CA (1) | CA2658782A1 (es) |
| CL (1) | CL2007002175A1 (es) |
| MX (1) | MX2009000947A (es) |
| PE (1) | PE20080948A1 (es) |
| RU (1) | RU2423354C2 (es) |
| TW (1) | TW200817393A (es) |
| WO (1) | WO2008014291A2 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA93548C2 (uk) | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| JP2010504965A (ja) * | 2006-09-27 | 2010-02-18 | アイアールエム・リミテッド・ライアビリティ・カンパニー | リンパ腫および骨髄腫を処置するための方法および組成物 |
| TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類 |
| ES2569941T3 (es) * | 2007-06-07 | 2016-05-13 | Novartis Ag | Derivados de bifenilcarboxamida como moduladores de la ruta de hedgehog |
| WO2009030952A2 (en) * | 2007-09-05 | 2009-03-12 | Astrazeneca Ab | Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| MX2010014066A (es) | 2008-06-16 | 2011-06-01 | Univ Tennessee Res Foundation | Compuestos para el tratamiento del cancer. |
| NZ591420A (en) * | 2008-09-17 | 2012-07-27 | Novartis Ag | Salts of n-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide |
| US8778927B2 (en) | 2008-10-01 | 2014-07-15 | Novartis Ag | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
| KR20120026534A (ko) * | 2009-06-11 | 2012-03-19 | 시에나 바이오테크 에스.피.에이. | 헤지호그 경로 길항제 및 그의 치료적 적용 |
| CN102802419A (zh) | 2010-01-07 | 2012-11-28 | 西莱瑟根治疗公司 | 刺猬(hedgehog)抑制剂 |
| WO2011109059A1 (en) | 2010-03-01 | 2011-09-09 | Gtx, Inc. | Compounds for treatment of cancer |
| FR2967498B1 (fr) | 2010-11-16 | 2015-01-02 | Centre Nat Rech Scient | Utilisation de derives de quinolinone comme outil de recherche |
| AU2012209295B2 (en) * | 2011-01-25 | 2016-06-30 | The Regents Of The University Of Michigan | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same |
| US20120207840A1 (en) * | 2011-02-10 | 2012-08-16 | Aura Biosciences, Inc. | Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment Of Non-Melanoma Skin Cancer |
| EP2653464B1 (en) * | 2012-04-20 | 2017-09-27 | Rohm and Haas Company | Benzylamine hydrophobe |
| WO2013188813A2 (en) * | 2012-06-15 | 2013-12-19 | The Regents Of The University Of California | Novel therapeutics for brain cancer |
| CN103570625A (zh) | 2012-07-19 | 2014-02-12 | 南京英派药业有限公司 | N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用 |
| EP3015459A1 (en) * | 2014-10-30 | 2016-05-04 | Sanofi | Benzylhydroxyde derivatives, preparation thereof and therapeutic use thereof |
| US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
| CA2977521C (en) | 2015-02-27 | 2024-03-19 | Curtana Pharmaceuticals, Inc. | 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors |
| AU2016271468B2 (en) | 2015-06-04 | 2020-01-02 | Sol-Gel Technologies Ltd. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
| TW202108559A (zh) | 2019-05-31 | 2021-03-01 | 美商醫肯納腫瘤學公司 | Tead抑制劑及其用途 |
| KR20220124176A (ko) | 2019-12-06 | 2022-09-13 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 치환된 테트라하이드로푸란 |
| AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2243337T3 (es) * | 1999-12-16 | 2005-12-01 | Schering Corporation | Imidazoles sustituidos antagonistas del receptor y5 del neuropeptido y. |
| BRPI0409097A (pt) | 2003-04-10 | 2006-04-11 | Avanir Pharmaceuticals | derivados de imidazol para tratamento de distúrbios alérgicos e hiperproliferativos |
| WO2005113513A2 (en) * | 2004-05-12 | 2005-12-01 | Chemocentryx | Aryl sulfonamides |
| US20090209573A1 (en) | 2004-10-28 | 2009-08-20 | Irm Llc | Compounds and compositions as hedgehog pathway modulators |
-
2007
- 2007-07-23 PE PE2007000953A patent/PE20080948A1/es not_active Application Discontinuation
- 2007-07-24 US US12/374,739 patent/US7928133B2/en not_active Expired - Fee Related
- 2007-07-24 AU AU2007276788A patent/AU2007276788A1/en not_active Abandoned
- 2007-07-24 KR KR1020097003730A patent/KR20090031789A/ko active IP Right Grant
- 2007-07-24 CA CA002658782A patent/CA2658782A1/en not_active Abandoned
- 2007-07-24 BR BRPI0714663-9A patent/BRPI0714663A2/pt not_active IP Right Cessation
- 2007-07-24 EP EP07840497A patent/EP2044065A2/en not_active Withdrawn
- 2007-07-24 MX MX2009000947A patent/MX2009000947A/es not_active Application Discontinuation
- 2007-07-24 RU RU2009106167/04A patent/RU2423354C2/ru not_active IP Right Cessation
- 2007-07-24 WO PCT/US2007/074268 patent/WO2008014291A2/en active Search and Examination
- 2007-07-24 JP JP2009521969A patent/JP2009544730A/ja active Pending
- 2007-07-25 TW TW096127107A patent/TW200817393A/zh unknown
- 2007-07-25 AR ARP070103302A patent/AR062100A1/es unknown
- 2007-07-25 CL CL200702175A patent/CL2007002175A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR062100A1 (es) | 2008-10-15 |
| CA2658782A1 (en) | 2008-01-31 |
| PE20080948A1 (es) | 2008-09-10 |
| MX2009000947A (es) | 2009-02-05 |
| EP2044065A2 (en) | 2009-04-08 |
| US7928133B2 (en) | 2011-04-19 |
| AU2007276788A1 (en) | 2008-01-31 |
| US20090312308A1 (en) | 2009-12-17 |
| BRPI0714663A2 (pt) | 2013-05-07 |
| WO2008014291A2 (en) | 2008-01-31 |
| KR20090031789A (ko) | 2009-03-27 |
| RU2423354C2 (ru) | 2011-07-10 |
| JP2009544730A (ja) | 2009-12-17 |
| RU2009106167A (ru) | 2010-08-27 |
| WO2008014291A3 (en) | 2008-04-03 |
| TW200817393A (en) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007002175A1 (es) | Compuestos derivados de 2,5-difenil-1h-imidazol, moduladores de la actividad de la senda de hedgehog, util para el tratamiento de cancer de piel sin melanoma, mieloma, linfoma, soriasis, cancer pancreatico, cancer de prostata, meduloblastoma, carcino | |
| CL2007003758A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer. | |
| MX2009011210A (es) | Inhibidores de mcl1 de indol 7-no sustituido. | |
| WO2010096371A3 (en) | Heterocyclic compounds which modulate the cb2 receptor | |
| CL2007002790A1 (es) | Compuestos derivados de 1h-indol y 1h-bencimidazol; composicion farmaceutica; y uso para el tratamiento de hipogonadismo, osteoporosis y cancer de prostata entre otros. | |
| BRPI0811907A2 (pt) | Anticorpos monoclonais contra claudina-18 para tratamento de câncer. | |
| CL2011000478A1 (es) | Compuestos derivados de 2-imidazol-propanamida sustituidos, activadores de glucoquinasa; composicion farmaceutica, util para tratar o retrasar la progresion o aparacion de la diabetes tipo ii o trastornos relacionados con la diabetes. | |
| HK1118019A1 (zh) | 用於治療癌症的包含ω-羧芳基取代的二苯基脲的藥物組合物 | |
| SMP200900085B (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative. | |
| CL2007003049A1 (es) | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. | |
| BRPI0814941A2 (pt) | Composição de tratamentode semente, e, método de tratamento de semente. | |
| WO2008131000A3 (en) | 7-substituted indole mcl-1 inhibitors | |
| EA201270049A1 (ru) | Дизамещенные фталазиновые антагонисты пути hedgehog | |
| SG170813A1 (en) | New compounds | |
| MX2009004047A (es) | Compuestos organicos. | |
| WO2007123892A3 (en) | Raf inhibitors and their uses | |
| BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
| BRPI0812027A2 (pt) | Composto 1,3 diona bicíclicos herbicidamente ativos. | |
| EA200971068A1 (ru) | Триазолиламинопиримидиновые соединения | |
| DOP2011000183A (es) | Polimorfos de(s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c][1,2-oxaborol-1-ol | |
| BRPI0615163A2 (pt) | composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5 | |
| BRPI0722096A2 (pt) | Compostos de 4-hidróxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il para modulação de atividade de b2-adrenorreceptor | |
| CL2007002858A1 (es) | Compuestos derivados de arilo-indol, inhibidores de la glicogeno sintasa quinasa-3-beta y/o moduladores de la actividad del canal n-metil-d-aspartato; formulacion farmaceutica, util para el tratamiento o prevencion de un desorden o trauma del snc, mi | |
| EA201170699A1 (ru) | Тетразамещенные пиридазины в качестве антагонистов пути hedgehog | |
| CL2008000681A1 (es) | Metodo de tratamiento de melanoma mediante el uso de compuestos derivados de 4-amino-5-fluoro-(benzoimidazol sustituido)-1h-quinolin-2-ona. |